Predictmedix Stock Price, News & Analysis

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) has deployed Safe Entry Stations at four office towers in Calgary and Edmonton, marking a significant move in partnership with Aspen Properties and Juiceworks. This 24-month contract allows for voluntary, AI-driven screening of infectious disease symptoms, including COVID-19, using non-invasive technology. The initiative aims to enhance safety in shared spaces, showcasing Predictmedix's advanced AI capabilities and providing visibility in the commercial real estate sector. The partnership highlights a proactive approach to tenant safety during ongoing health challenges.

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) has secured a 24-month contract to implement Safe Entry Stations within Flow Water Inc.'s operations in North America. Following a successful pilot test, this expansion will enhance health and safety protocols across Flow's facilities, significantly reducing absenteeism and improving employee security. The AI-driven technology, designed by infectious disease experts, quickly screens for COVID-19 symptoms, reinforcing Predictmedix's commitment to innovative health solutions amidst ongoing pandemic challenges.

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) has announced a partnership with JUICEWORKS EXHIBITS and CONNECTUS Global to deploy Safe Entry Stations, utilizing AI technology for assessing symptoms associated with infectious diseases like COVID-19. This innovative technology is designed to enhance safety in shared spaces, contributing to a return to normalcy in the community. The customizable Safe Entry Stations can be implemented in various settings, reflecting a significant advancement in health screening.

Predictmedix has appointed Kingswood Capital Markets to facilitate its potential NASDAQ listing under the symbol PMEDF. This move aims to enhance liquidity and capital market exposure. The listing application is subject to various regulatory requirements, including market maker retention and SEC registration. While this uplisting could significantly support Predictmedix's AI healthcare initiatives, there is no guarantee of NASDAQ acceptance. The company is dedicated to developing non-invasive AI tools for detecting impairment and screening for infectious diseases.

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) has announced a letter of intent to acquire Symp2Pass Inc. for approximately $5 million. The acquisition aims to enhance Predictmedix's AI-powered health screening solutions, capitalizing on Symp2Pass's strong revenue generation of $2.27 million in 2020. Predictmedix expects this strategic move will broaden its market reach, improve data collection, and increase revenue through innovative product integration. The acquisition is subject to customary closing conditions and expected to finalize within 30-60 days.

Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announced closing a non-brokered private placement raising $1,090,085 by issuing 3,114,529 units at $0.35 each. Each unit includes one common share and one warrant with an exercise price of $0.50 for two years. The company is expanding operations in marketing, hiring, and R&D following a successful product deployment at a Superbowl after-party, enhancing visibility. Funds will aid in developing AI tools for health and safety solutions in workplaces, amidst rising demand for infectious disease screening technology.

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) has completed a successful deployment of its Safe Entry Stations in Tampa Bay, marking its entry into the live event space. The stations scanned over 6,000 individuals at VIP Super Bowl events, providing rapid, non-invasive symptom screening with an average response time of 3-4 seconds per scan. The technology identified one COVID-19 case, demonstrating its effectiveness. The deployment received positive media coverage, with endorsements from event organizers praising its superior safety measures.

PredictMedix Inc. (CSE:PMED)(OTCQB:PMEDF) has partnered with Versus Systems, Inc. to innovate tools for clinical trials, highlighted by a letter of intent signed on September 29. The partnership aims to integrate Versus’ rewards platform with PredictMedix’s remote patient monitoring technology, facilitating patient recruitment and compliance in clinical trials, a sector valued at approximately $40 billion. This initiative responds to the challenges posed by the COVID-19 pandemic, which emphasizes the need for remote patient monitoring and data integrity in clinical research.